Temple University Hospital, Inc.

BROOKLYN, N.Y., Feb. 13, 2025 /PRNewswire/ -- Discover innovative cancer therapies, compassionate care, and a visionary approach to the future of oncology with Azriel Hirschfeld, MD. In the challenging landscape of cancer treatment, Dr. Azriel Hirschfeld is a beacon of innovation and hope. With over 15 years of experience as a board-certified oncologist, Dr. Hirschfeld has dedicated his career to pushing the boundaries of cancer therapy, offering renewed possibilities to patients at all stages of their cancer journey. Continue Reading Azriel Hirschfeld, MD Dr. Hirschfeld's formal medical education began at the Albert Einstein College of Medicine, followed by a residency in Internal Medicine at Temple University Hospital. He then completed a fellowship in Hematology and Oncology at the University of Maryland Medical Center's Greenebaum Cancer Center. This comprehensive education laid the foundation for his cutting-edge and innovative approach to cancer treatment. What sets Dr. Hirschfeld apart in the field of oncology is his unwavering commitment to exploring every possible avenue of treatment. His methods encompass a wide range of therapies, including standard of care treatment which can include traditional chemotherapy, immunotherapy, and targeted therapy. Dr. Hirschfeld is constantly innovating and improving upon the standard of care. Some of his strategies include using circulating tumor DNA to track progress in real time, as well as using liquid biopsies to determine the molecular profile of a tumor using that information to better target the tumor. Dr. Hirschfeld understands that some cancers require a multi-modality approach utilizing systemic chemotherapy with immunotherapy and targeted therapy. Each treatment plan is meticulously tailored to the specific profile of both the cancer and the patient, ensuring the most effective and personalized care. One of Dr. Hirschfeld's groundbreaking methods includes the strategic use of low-dose combination chemotherapy. This involves using multiple chemotherapy drugs—sometimes 4-6—at lower doses, which allows for safer combinations with better toxicity profiles. This method harnesses the synergistic interactions of multiple drugs, making it a powerful and effective approach for treating even the most resistant cancers. Dr. Hirschfeld has seen remarkable results with this approach, offering new hope to many patients. Dr. Hirschfeld's innovative spirit extends beyond his clinical practice into the realm of research. Throughout his career, he has focused on studying drug resistance, a critical area in oncology. His contributions to the field include pioneering work on multidisciplinary approaches to treating cholangiocarcinoma and developing 'multi-metronomic' algorithms for targeted therapy in resistant women's cancers. These research efforts not only advance our understanding of cancer biology but also translate directly into new, effective therapies for patients who may have exhausted traditional treatment options. But Dr. Hirschfeld's care goes far beyond innovative treatments and cutting-edge research. At the heart of his practice is a deep commitment to compassionate, patient-centered care. He understands that facing cancer is not just a medical journey but an intensely personal one. This empathetic approach allows him to provide not just medical treatment but also emotional support and hope. Accessibility is another cornerstone of Dr. Hirschfeld's practice. Unlike many doctors who may be difficult to reach, Dr. Hirschfeld prides himself on being available to his patients around the clock. This level of dedication fosters deep, meaningful relationships with his patients. Dr. Hirschfeld becomes more than just a doctor; he becomes a partner and advocate in their journey, celebrating their victories and supporting them through challenges. For those facing a cancer diagnosis, Dr. Hirschfeld offers renewed hope. His expertise in treating bile duct, colon, ovarian, breast, and pancreatic cancers, along with his willingness to tackle a variety of cancer types, makes him a dedicated ally in the fight against cancer. Dr. Hirschfeld's practice offers: Expertise in novel cancer treatments A track record of successful patient outcomes A personalized approach to cancer care Access and willingness to use off label therapies A compassionate and supportive care team State-of-the-art treatment facilities A focus on improving quality of life during treatment 24/7 on-call availability If you or a loved one are facing a cancer diagnosis, especially one that seems to have exhausted standard treatment options, contact Dr. Azriel Hirschfeld today. His innovative approaches, deep compassion, and unwavering dedication offer a new path forward in the fight against cancer. Don't wait to explore the possibilities—take the next step in your cancer journey with a true pioneer and expert in oncology care. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

German drugmaker Boehringer Ingelheim didn’t share any data behind the top-line result, instead promising that the efficacy and safety findings would be unveiled in the second quarter.\n Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications it will seek FDA approval for.The FIBRONEER-ILD trial saw 1,178 patients with progressive pulmonary fibrosis (PPF) receive either a 9 mg or 18 mg dose of the PDE4B inhibitor nerandomilast or placebo twice a day for 52 weeks. The study hit its primary endpoint of demonstrating an absolute change from baseline in forced vital capacity—a measure of the volume of air that a patient can breathe out—Boehringer said in a Feb. 10 release.The German drugmaker didn’t share any data behind the top-line result, instead promising that the efficacy and safety findings would be unveiled in the second quarter.“Initial data readouts of the FIBRONEER trials support a generally consistent safety and tolerability profile when compared to the phase 2 IPF study, with overall adverse events comparable to those seen in the placebo group,” the company said.Armed with the latest results, Boehringer said it will request that FDA and global regulators approve nerandomilast as a treatment for PPF, a type of interstitial lung disease. The company has already said it will seek approval for nerandomilast in IPF after proclaiming a win in a phase 3 trial for that lung disease in September 2024. Again, the company opted to hold back any concrete data from that trial for later in this year.When it comes to managing IPF, physicians already have Boehringer’s Ofev and Roche’s Esbriet. However, those drugs only slow the progression of fibrosis, while attempts to produce molecules that further slow, or ideally stop, progression have failed to prove their worth.By targeting phosphodiesterase 4B (PDE4B), nerandomilast is meant to have a mechanistic advantage over the incumbent products. Targeting PDE4 drives anti-inflammatory and antifibrotic effects, but attempts to develop oral inhibitors of the enzyme in respiratory diseases have been hindered by class-related systemic adverse events such as diarrhea and headaches.“The positive FIBRONEER-ILD topline result shows the potential of nerandomilast in progressive pulmonary fibrosis,” Shashank Deshpande, Head of Human Pharma at Boehringer, said in the release. “The hope is that the safety and tolerability profile we are initially seeing could potentially help to reduce treatment challenges.”

MEADOWBROOK, Pa., July 11, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Philip A. Villanueva, MD, ABNS, is acknowledged as a Trusted Healthcare Professional for his contributions to the field of Neurosurgery. Continue Reading Philip A. Villanueva, MD, ABNS Dr. Villanueva pursued higher education at Biscayne College (St. Thomas University) earning a Bachelor of Science degree with a double major in Biology and Chemistry and a minor in Theology and Philosophy. He then attended the University of Miami Miller School of Medicine where he received a Medical Degree and completed his general surgery internship and neurosurgery residency at the University of Miami, Jackson Memorial Medical Center. Board-certified in Neurological Surgery and in Neuro-Critical Care, Dr. Villanueva specializes in surgeries for brain injuries and neuro-critical care; treats aneurysms and all secondary issues regarding these conditions; and also manages the Neuroscience ICU consulting with neurologists. With more than 8 years at his current post, he has served as the Director of Neuro Trauma and Critical Care at Temple University Hospital in Philadelphia, PA. and is a Professor of Clinical Neurosurgery at the Lewis Katz School of Medicine at Temple University. A leader in his field, Dr. Villanueva a is Fellow of the American Association of Neurological Surgeons; is a member of the American Association of Neurological Surgeons; and serves on the subcommittee for neuro-critical care. He is also a neurosurgical board member for the Pennsylvania State Trauma Foundation, in which designates and re-certifies Trauma Centers in Pennsylvania. The doctor has also created a series of public service announcements to increase community awareness of brain trauma outside of his neurology practice. Dr. Villanueva has been recognized for excellence in service many times in his career, including the Best Doctors in America Award in Neurological Surgery (2019-2020). Dr. Villanueva would like to dedicate this honor to his mentors, Hubert Rosomoff, MD; Barth Green, MD; and Bradley Ruben, MD. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle